199 related articles for article (PubMed ID: 28326262)
1. Management of metastatic renal cell carcinoma - mini review.
Bharthuar A; Pandey H; Sood S
J Kidney Cancer VHL; 2015; 2(2):75-83. PubMed ID: 28326262
[TBL] [Abstract][Full Text] [Related]
2. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.
Wright I; Kapoor A
Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244
[TBL] [Abstract][Full Text] [Related]
3. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
4. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
5. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract][Full Text] [Related]
6. Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.
de Velasco G; Hamieh L; Mickey S; Choueiri TK
Urol Oncol; 2015 Dec; 33(12):538-45. PubMed ID: 26482392
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma.
Sepe P; Mennitto A; Corti F; Procopio G
Immunotargets Ther; 2020; 9():273-288. PubMed ID: 33224904
[TBL] [Abstract][Full Text] [Related]
8. Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.
Shinder BM; Rhee K; Farrell D; Farber NJ; Stein MN; Jang TL; Singer EA
Front Oncol; 2017; 7():107. PubMed ID: 28620578
[TBL] [Abstract][Full Text] [Related]
9. Advances in treatment of metastatic renal cell carcinoma.
Gong J; Gerendash B; Dizman N; Khan A; Pal SK
Curr Opin Urol; 2016 Sep; 26(5):439-46. PubMed ID: 27467136
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapeutics in refractory renal cell carcinoma.
Koshkin VS; Rini BI
Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
[TBL] [Abstract][Full Text] [Related]
11. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
Dudani S; de Velasco G; Wells JC; Gan CL; Donskov F; Porta C; Fraccon A; Pasini F; Lee JL; Hansen A; Bjarnason GA; Beuselinck B; Pal SK; Yuasa T; Kroeger N; Kanesvaran R; Reaume MN; Canil C; Choueiri TK; Heng DYC
JAMA Netw Open; 2021 Jan; 4(1):e2021869. PubMed ID: 33475752
[TBL] [Abstract][Full Text] [Related]
13. Emerging targeted therapies in metastatic renal cell carcinoma.
Matrana MR; Atkinson B; Jonasch E; Tannir NM
Curr Clin Pharmacol; 2011 Aug; 6(3):189-98. PubMed ID: 21827388
[TBL] [Abstract][Full Text] [Related]
14. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.
Joshi SS; Handorf EA; Zibelman M; Plimack ER; Uzzo RG; Kutikov A; Smaldone MC; Geynisman DM
Eur Urol; 2018 Sep; 74(3):387-393. PubMed ID: 29880274
[TBL] [Abstract][Full Text] [Related]
15. Metastatic Renal Cell Cancer-Systemic Therapy.
Joshi A; Sahu A; Noronha V; Patil V; Prabhash K
Indian J Surg Oncol; 2018 Mar; 9(1):97-104. PubMed ID: 29563746
[TBL] [Abstract][Full Text] [Related]
16. Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated With Targeted Therapies.
Yip SM; Heng DY; Tang PA
J Kidney Cancer VHL; 2016; 3(1):12-22. PubMed ID: 28326276
[TBL] [Abstract][Full Text] [Related]
17. The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma.
Nizam A; Schindelheim JA; Ornstein MC
Cancer Treat Res Commun; 2020 Feb; 23():100169. PubMed ID: 32126518
[TBL] [Abstract][Full Text] [Related]
18. Role of metastasectomy in the management of renal cell carcinoma.
Mikhail M; Chua KJ; Khizir L; Tabakin A; Singer EA
Front Surg; 2022; 9():943604. PubMed ID: 35965871
[TBL] [Abstract][Full Text] [Related]
19. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Jain RK; Gandhi S; George S
Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
[TBL] [Abstract][Full Text] [Related]
20. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
